Expertise in
13
conditions

Dr. Emerson C. Perin

Interventional Cardiology | Cardiology
Baylor College Of Medicine
7200 Cambridge St, Fl 10, 
Houston, TX 
Offers Telehealth
Expertise in
13
conditions
Baylor College Of Medicine
7200 Cambridge St, Fl 10, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emerson Perin is an Interventional Cardiologist and a Cardiologist in Houston, Texas. Dr. Perin is highly rated in 13 conditions, according to our data. His top areas of expertise are Atherosclerosis, Coronary Heart Disease, Angina, Bone Marrow Aspiration, and Angioplasty.

His clinical research consists of co-authoring 82 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Interventional Cardiology
Cardiology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baylor St Lukes Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

BAYLOR COLLEGE OF MEDICINE
7200 Cambridge St, Fl 10, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)
Enrollment Status: Terminated
Publish Date: October 09, 2025
Intervention Type: Genetic, Drug
Study Phase: Phase 3
A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris
A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Biological
Study Drug: Replication-Deficient Adenovirus Vector-Expressing cDNA/Genomic Hybrid VEGF
Study Phase: Phase 1/Phase 2
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Other, Drug
Study Drug: ARRY-371797 (PF-07265803)
Study Phase: Phase 3
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Device
Study Phase: Not Applicable
The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Device
Study Phase: Not Applicable
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Enrollment Status: Completed
Publish Date: January 10, 2022
Intervention Type: Biological, Other
Study Phase: Phase 3
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Enrollment Status: Unknown
Publish Date: November 01, 2019
Intervention Type: Combination product
Study Drug: Human Recombinant Fibroblast Growth Factor-1
Study Phase: Phase 2
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Enrollment Status: Terminated
Publish Date: June 23, 2017
Intervention Type: Device
Study Phase: Phase 3
View 7 Less Clinical Trials

82 Total Publications

Cell therapy for heart failure -recent progress and future directions.
Cell therapy for heart failure -recent progress and future directions.
Journal: Progress in cardiovascular diseases
Published: April 23, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Neal S. Kleiman
Interventional Cardiology | Cardiology
Expertise in
29
conditions
Dr. Neal S. Kleiman
Interventional Cardiology | Cardiology

Tmh Physician Associates PLLC

6565 Fannin St, 
Houston, TX 
 (0.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neal Kleiman is an Interventional Cardiologist and a Cardiologist in Houston, Texas. Dr. Kleiman is highly rated in 29 conditions, according to our data. His top areas of expertise are Aortic Valve Stenosis, Mitral Valve Regurgitation, Coronary Heart Disease, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. Dr. Kleiman is currently accepting new patients in some locations.

Biswajit Kar
Expertise in
40
conditions
Dr. Biswajit Kar
Interventional Cardiology | Cardiology | Advanced Heart Failure and Transplant Cardiology
Expertise in
40
conditions
Dr. Biswajit Kar
Interventional Cardiology | Cardiology | Advanced Heart Failure and Transplant Cardiology

UT Physicians

6411 Fannin St, 
Houston, TX 
 (1.0 miles away)
713-704-0093
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Biswajit Kar is an Interventional Cardiologist and a Cardiologist in Houston, Texas. Dr. Kar is highly rated in 40 conditions, according to our data. His top areas of expertise are Cardiogenic Shock, Aortic Valve Stenosis, Cardiomyopathy, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Kar is currently accepting new patients.

Expertise in
18
conditions
Dr. Richard W. Smalling
Cardiology | Interventional Cardiology
Expertise in
18
conditions
Dr. Richard W. Smalling
Cardiology | Interventional Cardiology

UT Physicians

6410 Fannin St, 
Houston, TX 
 (1.0 miles away)
Languages Spoken:
English, French, Italian, Spanish
See accepted insurances
Accepting New Patients

Richard Smalling is a Cardiologist and an Interventional Cardiologist in Houston, Texas. Dr. Smalling is highly rated in 18 conditions, according to our data. His top areas of expertise are Mitral Valve Regurgitation, Patent Foramen Ovale, Atrial Septal Defect (ASD), Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Smalling is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Perin's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile